Ex-EU drug watchdog head's consulting gig scrutinized

The European Medicines Agency has received some fresh requests to investigate former head Thomas Lonngren, who is now an industry consultant, for potential conflicts of interest committed before he left the agency late last year. Although the EMA has already consented to Lonngren's role as a consultant to drug companies, advocacy groups believe he bent some ethics rules when he arranged for the position while still working for the agency. They want the agency to take another look into the matter, Pharmalot reported. Article

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.